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Probiotic supplements containing 
Lactobacillus reuteri does not affect the levels 
of matrix metalloproteinases and interferons 
in oral wound healing
Svante Twetman1* , Anne Marie Lynge Pedersen1 and Tulay Yucel‑Lindberg2
Abstract 
Objective: The use of beneficial bacteria may stimulate wound healing. We performed a randomized, placebo‑
controlled double‑blind cross‑over study comprising ten healthy volunteers. The aim was to investigate the impact of 
topical and systemic applications of probiotic lactobacilli (Lactobacillus reuteri) on the healing of standardized wounds 
(punch biopsies) in the oral mucosa. The expression of selected matrix metalloproteinases (MMP’S) and interferons 
(IFN’s) was analyzed with multiplex immunoassays in the wound exudate during the first healing week (day 2, 5 and 
8).
Results: All participants completed the study and in all cases, the healing after the punch biopsies was uneventful. 
The concentrations of MMP‑1, MMP‑2, MMP‑3 decreased with time in both the test‑ and control group. The MMP lev‑
els were consistently lower during the probiotic intervention when compared with placebo but the differences were 
not statistically significant. Likewise, the concentrations if IFN‑alpha2, IFN‑beta and IFN‑gamma decreased with time 
with no significant differences between the test and placebo interventions. Within the limitations of this pilot study, 
we were unable to demonstrate an influence of probiotic supplements containing L. reuteri on the concentrations of 
selected matrix metalloproteinases and interferons from mucosal wounds within 1 week after a standardized punch 
biopsy.
Trial registration ClinicalTrials.gov Identifier NCT03210779. Date of registration: July 7, 2017
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Introduction
Matrix metalloproteinases (MMP’s) is a family of pro-
teolytic enzymes basically involved in tissue remod-
eling, wound healing and inflammation [1]. MMP’s 
are also suggested to play a role in biofilm-mediated 
oral diseases [2, 3] with elevated salivary concentra-
tions in patients with active caries [4] and in patients 
with severe periodontitis [5]. The use of lactobacilli-
derived probiotic bacteria has in recent years emerged 
as a novel strategy for the management of dysbiotic 
oral biofilms [6, 7] but little is known on its possible 
influence on the MMP’s in the oral cavity. Staab and 
co-workers [8] reported reduced levels of MMP-3 in 
gingival crevicular fluid (GCF) from healthy volun-
teers following intake of milk containing L. casei. Sig-
nificantly decreased levels of MMP-8 have also been 
shown in patients with chronic periodontitis after 
intake of lozenges with Lactobacillus reuteri when com-
pared with placebo [9]. On the other hand, Jäsberg et al. 
[10] demonstrated increased concentrations of MMP-9 
in healthy volunteers after a 4-week intake of B. lac-
tis and L. rhamnosus GG. Interferon (IFN) is a group 
of signaling proteins produced and released by host 
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cells in response to the presence of pathogens or tissue 
damage. Previous research has indicated that probiotic 
treatment can decrease the expression of IFN-gamma 
from T-cells [11] and in saliva [12]. We have recently 
investigated L. reuteri in the context of oral wound 
healing and found elevated levels of ligand members 
of the tumor necrosis factor (TNF) superfamily, as well 
as Interleukin 8 in the wound exudate after a standard-
ized punch biopsy [13]. In this communication, the lev-
els of MMP-1, MMP-2, MMP-3, IFN-alpha2, IFN-beta 
and IFN-gamma are reported. The null hypothesis was 
that the concentrations would not differ from those 
obtained when exposed to placebo.
Main text
Materials and methods
The study group consisted of 10 healthy volunteers 
of both sexes (8 females, 2 males). The mean age was 
29.5  years (range 21–66  years) and all were employ-
ees or students at the University Hospital. The inclu-
sion criteria were non-compromised general and oral 
health and no regular intake of pharmaceuticals with 
the exception of contraceptives. Exclusion criteria were 
(a) smoking, (b) any severe allergy or bleeding disorder, 
and (c) a regular intake probiotic products. All partici-
pants had a normal appearing oral mucosa and no signs 
of dental caries or periodontal disease.
Study design
The study had a randomized, placebo-controlled, dou-
ble-blind cross-over design. The protocol was approved 
by The Research Ethics Committee of the Capital 
Region of Denmark (H-16025546) and the study was 
registered at Clintrials.gov (NCT03210779). During a 
1-week run-in period, the participants were assigned 
to let an active or placebo lozenge slowly dissolve in 
their mouth, two times per day. After 8 days, a biopsy 
was taken under local anesthesia containing adrenalin 
with aid of a standardized punch (4  mm diameter) in 
the free buccal oral mucosa in the upper left or right 
premolar region. After compression with cotton gauges 
for 30 min, the created wound was left uncovered and 
no sutures were used. The subjects were thoroughly 
instructed to continue with their assigned lozenges for 
another 8 days. In addition, they were asked to topically 
apply one drop of oil (probiotic or placebo) directly 
on the wound, once daily for 8 days with aid of a plas-
tic micro-brush. No food or nutritional restrictions 
were given, and all subjects were asked to maintain 
their normal oral hygiene routines during the course 
of the study. After a 4-week washout period, all the 
procedures were repeated a second time with either the 
test or placebo lozenges/oil.
Intervention
The test lozenges (BioGaia ProDentis, BioGaia AB, Swe-
den) contained a mix of two probiotic strains, L. reuteri 
DSM 17938 and ATCC PTA 5289, with at least 5 × 108 
live bacteria of each strain per lozenge. The placebo loz-
enges had an identical composition, shape and taste, but 
without active bacteria. The test oil contained the same 
probiotic strains with a concentration of 2 ×  108 CFU/
mL. The study products were provided in identical plas-
tic containers, separated by a color code. The compliance 
was checked through a logbook that was filled in on a 
daily basis.
Sample collection and biochemical assays
All subjects were recalled after 2, 5 and 8 days for check-
ups. The wound healing was assessed with a 4-level clini-
cal score as described in Additional file 2. Exudate from 
the wounds was collected by sterile circular standard 
filter papers  (Sialostrip®, ProFlow™ Inc., Amenityville, 
MY, USA) that were applied on top of the wound for 20 s. 
The volume of liquid was determined with a  Periotron® 
8000 (ProFlow). The filter papers were diluted in 150 µL 
of PBS (pH 7.4) with 0.05% Tween-20, vortexed for 30 s 
and stored at − 80 °C until further analysis. Commercial 
multiplex immunoassay kits (human inflammation panel, 
Bio-Rad, Hercules, CA, USA) were used to determine 
the MMP and interferon levels in exudate samples, han-
dled according to manufacturer’s protocol. The analyzed 
enzymes (sensitivities in pg/mL, in parentheses) were 
MMP-1 (33.7), MMP-2 (39.7) and MMP-3 (28.5) and the 
cytokines were IFN-alpha2 (0.7), IFN-beta (2.0) and IFN-
gamma (0.05). Total protein concentration, expressed as 
mg/mL, was analyzed using Bio-Rad DC protein assay 
(Bio-Rad, Solna, Sweden). The protein levels were meas-
ured in duplicates and the levels of MMPs and IFNs were 
analyzed in single within one analytical run, as previously 
described [13].
Statistical methods
All data were processed with the IBM SPSS software 
(version 25.0, Chicago, USA). The differences between 
groups were analyzed by Wilcoxon unpaired test. P-val-
ues less than 0.05 were considered as statistically signifi-
cant. The blinding was not unveiled until the statistical 
analyses were concluded.
Results and discussion
All participants completed the study and in all cases, 
the healing after the punch biopsies was uneventful 
(Additional file 1). There were no statistically significant 
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differences in the oral wound healing pattern between 
test and placebo (Additional file 2). The mean concentra-
tion of total protein and the selected MMP’s are shown 
in Table 1. The amount of wound exudate, as well as the 
concentration of total protein, decreased with time in a 
similar way in both groups. The MMP levels were con-
sistently lower during the probiotic intervention when 
compared with placebo but the differences were not 
statistically significant. The mean concentrations of 
IFN-alpha2, IFN-beta and IFN-gamma are presented in 
Table  2. Also here, the measured levels decreased with 
time but with no significant differences between the test 
and placebo interventions.
To our knowledge, this is the first study to investigate 
the possible impact of topical and systemic administra-
tion of probiotic supplements on a panel of inflammatory 
mediators related to oral wound healing. In particular, 
data on the concentration of MMP’s and IFN’s in the 
exudate have not previously been reported. We used a 
well-controlled cross-over design with run-in and wash-
out periods of 1 and 4  weeks, respectively. Importantly, 
the participating subjects were exposed to the test or 
placebo interventions in a randomized order. Further-
more, the volunteers were healthy and well-fed and the 
compliance with the study protocol was excellent [13]. 
As we were unable to demonstrate any significant differ-
ences in the amounts of MMP’s and IFN’s between the 
two interventions, the null hypothesis was accepted. The 
results remained unaltered when the concentrations were 
related to the total amount of protein in the samples and 
to the output (volume/time) of the exudate.
The healing of oral mucosal wounds follows a well-
described pathway of hemostasis, inflammation, prolif-
eration and remodeling, regulated by a complex network 
of growth factors, cytokines and chemokines [14]. Inter-
estingly, laboratory data indicate that IFN-gamma may 
regulate MMP’s involved in connective tissue turnover in 
the presence of TNF-alpha [15]. Previous clinical studies 
have suggested that beneficial bacteria may accelerate the 
healing of surgical wounds as well as burns and diabetic 
foot ulcers [16–19]. The precise mechanism of action is 
not fully known but a systemic influence on the immune 
response by balancing pro- and anti-inflammatory agents 
has been described [20, 21]. Based on previous research, 
we had hoped to unveil decreased amounts of MMP-3 
[8] and IFN-gamma [12] in connection with the probi-
otic intervention, albeit the former analyses were carried 
out in gingival crevicular fluid and saliva, respectively. 
The fact that we were unable to disclose these events in 
the present pilot study does not exclude the possibil-
ity that beneficial bacteria can play a role in oral inflam-
mation. We noticed a tendency towards lower levels of 
MMP’s after 8  days in the probiotic group but the lim-
ited number of participants and the large inter-individ-
ual variations recorded in the exudates made the study 
underpowered with respect to the biochemical variables. 
Another open question is whether or not there is a dose-
relationship between exposure of oral probiotics and the 
expression of inflammatory mediators in saliva or gingi-
val crevicular fluid. Thus, an expanded clinical trial with 
focus on recurrent or chronic oral wounds could be justi-
fied as such wounds are prevalent and a therapeutic chal-
lenge in an aging population.
Table 1 Amount of  wound exudate and  concentration 
of  total protein and  selected MMP’s in  wound exudate 
collected 2, 5 and  8  days after  a  standardized punch 
biopsy, with  and  without exposure to  probiotic 
supplements
Values denote mean and standard deviation (SD)
Variables Day 2 Day 5 Day 8
Wound exudate, µL
 Test 2.01 (0.54) 1.05 (0.46) 0.40 (0.29)
 Placebo 2.00 (0.65) 0.99 (0.80) 0.34 (0.21)
Total protein, mg/mL
 Test 1.50 (0.22) 0.53 (0.18) 0.30 (0.13)
 Placebo 1.84 (0.28) 0.52 (0.06) 0.22 (0.04)
MMP‑1, pg/mL ×103
 Test 3.51 (2.47) 3.05 (5.31) 0.86 (1.38)
 Placebo 3.90 (3.84) 3.93 (4.77) 2.17 (5.85)
MMP‑2, pg/mL ×103
 Test 1.64 (0.75) 0.51 (0.56) 0.04 (0.06)
 Placebo 1.57 (1.43) 0.76 (0.92) 0.19 (0.48)
MMP‑3, pg/mL ×103
 Test 1.06 (0.71) 0.67 (0.44) 0.16 (0.21)
 Placebo 1.33 (1.02) 0.73 (0.62) 0.43 (1.20)
Table 2 Concentration of  selected interferons (pg/
mL) in  wound exudate collected 2, 5 and  8  days 
after  a  standardized punch biopsy, with  and  without 
exposure to probiotic supplements
Values denote mean and standard deviation (SD)
Variables Day 2 Day 5 Day 8
IFN‑alpha2
 Test 23.5 (15.1) 13.7 (8.4) 4.2 (4.0)
 Placebo 30.3 (7.7) 17.6 (19.0) 11.5 (25.3)
IFN‑beta
 Test 20.2 (13.5) 14.0 (9.0) 4.1 (2.0)
 Placebo 24.2 (6.7) 11.6 (7.6) 6.7 (9.2)
IFN‑gamma
 Test 9.0 (6.3) 5.0 (4.3) 0.1 (0.2)
 Placebo 11.4 (4.0) 4.2 (4.5) 1.9 (5.8)
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Conclusion
Within the limitations of this study, we were unable 
to demonstrate an influence of probiotic supplements 
containing L. reuteri on the concentrations of selected 
MMP’s and IFN’s in the wound exudate within 1  week 
after a standardized punch biopsy.
Limitations
This was a pilot study and the sample size (α = 0.05 and 
β = 0.2) was estimated on clinical endpoints (healing 
score, pain and discomfort) rather than on any biochemi-
cal endpoint. The data were obtained from the healing of 
fresh oral wounds and the findings may not be general-
ized to chronic wounds. Compliance was not verified by 
primer-specific polymerase chain reaction (PCR) analy-
ses of L. reuteri in the wound exudate.
Additional files
Additional file 1. Oral wound healing 2, 5 and 8 days after a standardized 
punch biopsy.
Additional file 2. Distribution of clinical healing scores after a standard‑
ized punch biopsy in the oral mucosa with exposure to probiotic supple‑
ments or placebo.
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